PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC

Table 1

Baseline characteristics.

Characteristics	(%)
Age, median (range in years)	65 (28-94)
≤65	73 (50.7%)
>65	71 (49.3%)
Gender
Male	92 (63.9%)
Female	52 (36.1%)
Histology
Adenocarcinoma	101 (70.1%)
Squamous cell carcinoma	19 (13.2%)
Adenosquamous carcinoma	5 (3.5%)
NSCLC	19 (13.2%)
T ()
1	9 (6.7%)
2	25 (18.5%)
3	22 (16.3%)
4	79 (58.5%)
N
0	13 (9.0%)
1	11 (7.6%)
2	30 (20.8%)
3	90 (62.5%)
M
0	24 (16.7%)
1	120 (83.3%)
Stage
I/II	6 (4.2%)
III	18 (12.5%)
IV	120 (83.3%)
EGFR ()
Mutation	59 (52.4%)
Wild type	65 (47.6%)
ALK ()
Positive	6 (5.0%)
Negative	115 (95.0%)
PD-L1 (Dako22C3) ()
<1%	53 (41.7%)
1-49%	56 (44.1%)
≥50%	18 (14.2%)
PD-L1 (SP142 TC/IC) ()
<1%/<1%	85 (64.4%)
Intermediate	33 (25.0%)
≥50%/>10%	14 (10.6%)
PD-L1 (Dako28-8) ()
<1%	54 (49.1%)
1-49%	42 (38.2%)
≥50%	14 (12.7%)

NSCLC: non-small cell lung cancer; TC: tumor cells; IC: immune cells.